Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infection, Human Immunodeficiency Virus

Conditions

Infection, Human Immunodeficiency Virus

Trial Timeline

Jun 1, 2012 → Aug 1, 2012

NCT ID

NCT01622790

About Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg

Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mg is a phase 1 stage product being developed by Shionogi for Infection, Human Immunodeficiency Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT01622790. Target conditions include Infection, Human Immunodeficiency Virus.

What happened to similar drugs?

20 of 20 similar drugs in Infection, Human Immunodeficiency Virus were approved

Approved (20) Terminated (3) Active (0)

✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved

✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

✅Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved

✅Cefiderocol + Ampicillin-sulbactam + Colistin + MeropenemJohnson & JohnsonApproved

✅Darunavir + Etravirine + Emtricitabine/tenofovir disoproxil fumarate + Raltegravir + Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs) + Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableAbbVieApproved

✅Lopinavir/RitonavirAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01622790	Phase 1	Completed	Jun 1, 2012	Aug 1, 2012	Infection, Human Immunodeficiency Virus
NCT01366547	Phase 1	Completed	Jun 1, 2011	Jul 1, 2011	Healthy Subjects

Competing Products

20 competing products in Infection, Human Immunodeficiency Virus

See all competitors

Product	Company	Stage	Hype Score
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1944	Moderna	Phase 1	0
mRNA-1189	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1653	Moderna	Phase 1	0
mRNA-1195.1	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
DFA-02 Antibiotic Gel + DFA-02 Placebo Gel	Dr. Reddy's Laboratories	Phase 2	32
DFA-02 + Placebo	Dr. Reddy's Laboratories	Phase 1/2	29
Levofloxacin + Levofloxacin	Dr. Reddy's Laboratories	Approved	36
BSG005	Alkem Laboratories	Phase 1/2	39
Zotatifin + Placebo	eFFECTOR Therapeutics	Phase 1	19
AAVLP-HPV + Placebo	2A Pharma	Phase 1	19
CT-P59	Celltrion	Phase 1	29
CT-P63 + Placebo	Celltrion	Phase 1	29